ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2183

Evolution of Lymphoma Predictors in Primary Sjogren’s Syndrome by Data Driven Analysis in Harmonized Patients

Andreas Goules1, Loukas Chatzis2, Vasileios pezoulas3, Francesco Ferro4, Valeria Manfrè5, Dimitrios Fotiadis3, Luca Quartuccio Quartuccio6, Chiara Baldini7, Salvatore De Vita5 and Athanasios Tzioufas1, 1Dept. of Pathophysiology, School of Medicine, University of Athens, Athens, Greece, 2Dept. of Pathophysiology, School of Medicine, University of Athens, Cholargos Athens, Greece, 3Unit of Medical Technology and Intelligent Information Systems, Dept. of Materials Science and Engineering, University of Ioannina, Ioannina, Greece, 4Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, 5Clinic of Rheumatology, Dept. of Medical and Biological Sciences, Udine University, Udine, Italy, 6Rheumatology Division, Department of Medicine, University of Udine, Udine, Italy, 7University of Pisa, Pisa, Italy

Meeting: ACR Convergence 2023

Keywords: Rheumatoid Factor, Sjögren's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (2177–2194) Sjögren’s Syndrome – Basic & Clinical Science Poster II

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Lymphoma is the most serious complication of primary Sjogren’s
syndrome (pSS), occurring as a late sequel during disease course. So far, lymphoma
predictors have been identified only at the time of pSS diagnosis in single center cohorts
using classical logistic regression models. The current work aims to study the evolution of
lymphoma predictors towards lymphoproliferation by employing data driven analysis on
totally harmonized pSS patients.

Methods: Two curated and harmonized datasets with pSS patients from3 centers (Athens,
Piza, Udine) were constructed to be analyzed for lymphoma predictors at two different time
points before lymphoma diagnosis. Each dataset incorporated the same set of 30 clinically
useful features covering the major aspects of the disease (Table 1, 2). The first dataset
included 80 lymphoma patients and non-lymphoma controls (1:1 ratio), representing the
time point of pSS diagnosis and the second dataset 68 lymphoma and non-lymphoma
controls (1:1 ratio) representing the time point of 3-4 years before lymphoma diagnosis. All
included patients fulfilled the 2016 ACR/EULAR criteria and non-lymphoma controls were
matched according to age, gender, disease duration from pSS diagnosis to last follow up and
treatment modalities. Systemic manifestations were defined as described in the ESSDAI
domains and for those not included in the ESSDAI system, either by tissue biopsy or by
applying international consensus criteria. A Fast-Correlation based feature selection
(FCBF)/logistic regression (LR) model with lymphoma as an outcome, was applied on both
datasets as described previously (1).

Results: Regarding the time point of pSS diagnosis, 5 prominent features in terms of
magnitude of order were identified by the FCBF algorithm as potential predictors including
rheumatoid Factor (RF), cryoglobulinemia, ACA pattern, ESSDAI≥5 and lacrimal gland
enlargement of which only RF was finally proven an independent lymphoma predictor
(Table 1). For the second time point of 3-4 years before lymphoma diagnosis, a similar set of
prominent features was found by the FCBF algorithm with the exception of lacrimal gland
enlargement and cryoglobulinemia while RF and ESSDAI≥5 were identified as independent
lymphoma risk factors (Table 2). Both FCBF/LR models had good overall performance after
10-fold cross validation strategy (pSS diagnosis: accuracy=63%, sensitivity=63%,
specificity=63%, AUC=76% and for the second time point of 3-4 years before lymphoma
diagnosis: accuracy=65%, sensitivity=65%, specificity=71%, AUC=75%).

Conclusion: Rheumatoid factor is the earliest and more persistent pSS associated lymphoma
predictor while high ESSDAI≥5 in combination with RF connote an advanced stage across the
lymphomagenesis process, predicting the occurrence of lymphoma in approximately 4 years
before.

Supporting image 1

FCBF-based multivariable logistic regression analysis for lymphoma predictors at pSS diagnosis

Supporting image 2

FCBF-based multivariable logistic regression analysis for lymphoma predictors at 3_4 years before lymphoma diagnosis


Disclosures: A. Goules: None; L. Chatzis: None; V. pezoulas: None; F. Ferro: None; V. Manfrè: None; D. Fotiadis: None; L. Quartuccio: None; C. Baldini: GlaxoSmithKlein(GSK), 6, Horizon, 6, Sanofi, 6; S. De Vita: None; A. Tzioufas: None.

To cite this abstract in AMA style:

Goules A, Chatzis L, pezoulas V, Ferro F, Manfrè V, Fotiadis D, Quartuccio L, Baldini C, De Vita S, Tzioufas A. Evolution of Lymphoma Predictors in Primary Sjogren’s Syndrome by Data Driven Analysis in Harmonized Patients [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/evolution-of-lymphoma-predictors-in-primary-sjogrens-syndrome-by-data-driven-analysis-in-harmonized-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evolution-of-lymphoma-predictors-in-primary-sjogrens-syndrome-by-data-driven-analysis-in-harmonized-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology